<DOC>
	<DOCNO>NCT02033941</DOCNO>
	<brief_summary>Alzheimer Disease ( AD ) progressive brain disease generally know senile dementia . Our propose study establish safety pharmacokinetics Meganatural-AZ GSPE AD subject . As secondary measure , also provide essential human data guide design future study test efficacy GSPE mitigate cognitive deterioration AD patient .</brief_summary>
	<brief_title>Phase 2 Study Examine Grape Seed Extract Anti-Oligomerization Agent Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description>This study aim establish safety pharmacokinetics Meganatural-AzÂ® GSPE subject Alzheimer 's disease . As secondary goal , clinical biomarker index therapeutic efficacy also evaluate . The propose study provide essential human data necessary guide design future study test efficacy GSPE mitigate cognitive deterioration AD patient .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Grape Seed Extract</mesh_term>
	<criteria>NINCDS/ADRDA criterion probable AD MMSE 1226 Treatment cholinesterase inhibitor NMDA ( NmethylDasparate ) antagonist stable dose least 12 week Home monitoring available supervision medication Caregiver available accompany patient visit willing participate study informant Fluent English Spanish Medical stability study confirm review record , internist 's physical exam , neurological exam , laboratory test Stable dos nonexcluded medication No evidence hepatic insufficiency Able swallow oral medication Ability participate informed consent process History hypotension unstable hypertension Active hepatic renal disease Use another investigational drug within past two month History clinically significant stroke History seizure head trauma disturbance consciousness within past two year Major mental illness include psychotic disorder , bipolar disorder , major depressive episode remission le 12 month Women childbearing age unless use effective birth control least one year postmenopausal surgically menopausal Any ferrous metallic material contraindicate MRI Medication Exclusions Current use drug significant anticholinergic antihistaminic property</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Grapeseed Extract</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Meganatural-AZ</keyword>
	<keyword>anti-oligomerization</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Dietary Supplement</keyword>
	<keyword>Nutraceutical</keyword>
</DOC>